Poseida Therapeutics (NASDAQ:PSTX) Earns “Buy” Rating from HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $20.00 target price on the stock.

Poseida Therapeutics Stock Performance

Poseida Therapeutics stock opened at $2.76 on Friday. The stock’s fifty day moving average price is $2.81 and its two-hundred day moving average price is $2.92. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. Poseida Therapeutics has a one year low of $1.87 and a one year high of $4.27.

Institutional Investors Weigh In On Poseida Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bayesian Capital Management LP bought a new position in Poseida Therapeutics in the 1st quarter valued at about $33,000. Marshall Wace LLP bought a new position in Poseida Therapeutics in the second quarter valued at approximately $31,000. Rothschild Investment LLC acquired a new position in Poseida Therapeutics during the second quarter valued at approximately $35,000. Principal Financial Group Inc. bought a new stake in Poseida Therapeutics during the second quarter worth $35,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Poseida Therapeutics in the 3rd quarter valued at $46,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.